Korea Union Pharmaceutical Rises 7.1% Amid COVID-19 (Plasma Therapy/Plasma Therapeutics) Theme Uptrend

On the 7th, the COVID-19 (plasma treatment/plasma therapeutics) theme showed strength by rising 3.03% compared to the previous day, with Korea Union Pharmaceutical, a stock attracting attention in this sector, soaring 7.1% from the previous day. Korea Union Pharmaceutical is known as a manufacturer of prescription drugs.

[Graph] Major stock price changes in the COVID-19 (plasma treatment/plasma therapeutics) theme

According to provisional data compiled at 11:04 AM, foreign investors are net buying 0.52 ten thousand shares of Korea Union Pharmaceutical.

[Table] Net trading volume of foreigners and institutions (unit: ten thousand shares)

According to the analysis by Thinkpool Robo Algorithm RASSI, Korea Union Pharmaceutical’s quant financial score is 11.94 points, which is lower in stability, profitability, and growth compared to the average of other stocks related to COVID-19 (plasma treatment/plasma therapeutics). This can be interpreted as Korea Union Pharmaceutical having relatively low investment attractiveness compared to other stocks from a financial perspective. On the other hand, SMAC ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of the Robo Algorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.